NCT06586697 2024-09-19
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
Henan Cancer Hospital
Phase 2 Unknown
Clinical Trials
155 trialsNCT06293833 2024-03-05
ZORALCS
University Hospital, Antwerp
Phase NA Unknown
NCT05829057 2024-02-13
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Zhejiang University
Phase 1 Unknown
NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
NCT05296603 2024-01-10
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Unknown
NCT06187740 2024-01-09
Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
Fudan University
Phase 1 Unknown
NCT05991180 2023-12-27
Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Unknown
NCT04985851 2023-12-01
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
Shanghai Chest Hospital
Phase NA Unknown
NCT04253145 2023-11-18
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
Fundacion Oncosur
Phase 1/2 Unknown
NCT05228496 2023-09-26
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05975944 2023-08-04
Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Unknown
NCT05731518 2023-07-14
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Unknown
NCT05901584 2023-06-18
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Second Affiliated Hospital of Zunyi Medical University
Phase 2 Unknown
NCT05780307 2023-06-07
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Unknown
NCT03568097 2023-06-02
PAVE
Hellenic Cooperative Oncology Group
Phase 2 Unknown
NCT05886075 2023-06-02
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT05873790 2023-05-24
Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study
The First Hospital of Jilin University
Unknown
NCT04542369 2023-05-03
Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT05826756 2023-04-28
PEER
LUNGevity Foundation
Unknown
NCT00526396 2023-03-24
STAD-1
National Cancer Institute, Naples
Phase 3 Unknown
NCT05761977 2023-03-09
DRIVE
Hellenic Cooperative Oncology Group
Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05668767 2022-12-30
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Beijing Chest Hospital
Phase 2 Unknown
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04996771 2022-11-14
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT00100256 2022-11-07
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Andarix Pharmaceuticals
Phase 1/2 Unknown
NCT05527821 2022-09-06
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05205421 2022-08-05
A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer
The First Affiliated Hospital of Bengbu Medical University
Phase 1 Unknown
NCT05027100 2022-07-01
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
Guangzhou University of Traditional Chinese Medicine
Phase NA Unknown
NCT05354700 2022-05-04
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2 Unknown
NCT05162196 2022-05-02
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Phase 2 Unknown
NCT03711305 2022-04-18
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05320458 2022-04-11
Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer
Hasan Kalyoncu University
Phase NA Unknown
NCT01441349 2022-04-06
Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05299255 2022-03-28
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT03221400 2022-02-17
PEN-866 in Patients With Advanced Solid Malignancies
Tarveda Therapeutics
Phase 1/2 Unknown
NCT02446704 2022-02-07
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Phase 1/2 Unknown
NCT05191849 2022-01-14
Circulating EV Long RNA Profiles in SCLC
Fudan University
Phase NA Unknown
NCT05158491 2022-01-05
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
JenKem Technology Co., Ltd.
Phase 1/2 Unknown
NCT04901754 2021-12-08
CAMERA
Henan Cancer Hospital
Phase 2 Unknown
NCT04947774 2021-09-22
Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
ChineseAMS
Unknown
NCT04985201 2021-08-09
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04698941 2021-07-29
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04890795 2021-05-18
A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer
Advenchen Laboratories, LLC
Phase 1/2 Unknown
NCT04790955 2021-03-10
Effect of Combination Therapy on SCLC After Initial Treatment Failure
First Affiliated Hospital of Harbin Medical University
Unknown
NCT04782089 2021-03-04
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer
Qilu Hospital of Shandong University
Phase NA Unknown
NCT04691063 2021-02-26
The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04757779 2021-02-17
A Single-arm, Phase â…¡ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04731909 2021-02-10
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
Third Military Medical University
Phase NA Unknown